Literature DB >> 23571507

CD300c is an activating receptor expressed on human monocytes.

Venkateswara R Simhadri1, John L Mariano, Aleksandra Gil-Krzewska, Qing Zhou, Francisco Borrego.   

Abstract

Human CD300 molecules comprise a family of receptors that regulate many immune cell processes. They are mostly expressed on myeloid cells, although expression of two members, CD300a and CD300c, has also been described on lymphocytes. However, due to the lack of specific antibodies that distinguish between these two receptors, it has been difficult to determine the expression pattern and function of CD300a and CD300c in primary cells. Here, we have identified a specific monoclonal antibody, clone TX45, that recognizes only CD300c and show that within freshly isolated blood leukocytes, monocytes are the only cells that express CD300c on the cell surface. In vitro differentiation experiments revealed that CD300c is differentially expressed on different monocyte-derived cells, including macrophages and dendritic cells. Furthermore, TLR ligands LPS and flagellin dynamically regulate the expression of CD300c. Cross-linking of this receptor with clone TX45 monoclonal antibody induced calcium mobilization, upregulation of the costimulatory molecule CD86 and the production of inflammatory cytokines. Importantly, LPS-mediated production of inflammatory cytokines by monocytes was further enhanced if CD300c was simultaneously engaged by the agonist antibody. Altogether, our results show that human CD300c is an activating receptor expressed on monocytes and that it has a potential role in inflammatory responses.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23571507      PMCID: PMC6741618          DOI: 10.1159/000350523

Source DB:  PubMed          Journal:  J Innate Immun        ISSN: 1662-811X            Impact factor:   7.349


  39 in total

1.  Molecular cloning of a novel member of the immunoglobulin gene superfamily homologous to the polymeric immunoglobulin receptor.

Authors:  D G Jackson; D N Hart; G Starling; J I Bell
Journal:  Eur J Immunol       Date:  1992-05       Impact factor: 5.532

2.  CD300 heterocomplexes, a new and family-restricted mechanism for myeloid cell signaling regulation.

Authors:  Agueda Martínez-Barriocanal; Emma Comas-Casellas; Simo Schwartz; Margarita Martín; Joan Sayós
Journal:  J Biol Chem       Date:  2010-10-19       Impact factor: 5.157

3.  The CMRF-35 mAb recognizes a second leukocyte membrane molecule with a domain similar to the poly Ig receptor.

Authors:  B J Green; G J Clark; D N Hart
Journal:  Int Immunol       Date:  1998-07       Impact factor: 4.823

Review 4.  The CD300 molecules: an emerging family of regulators of the immune system.

Authors:  Francisco Borrego
Journal:  Blood       Date:  2013-01-04       Impact factor: 22.113

5.  Specific lipid recognition is a general feature of CD300 and TREM molecules.

Authors:  John P Cannon; Marci O'Driscoll; Gary W Litman
Journal:  Immunogenetics       Date:  2011-07-29       Impact factor: 2.846

Review 6.  Structure and function of major histocompatibility complex (MHC) class I specific receptors expressed on human natural killer (NK) cells.

Authors:  Francisco Borrego; Juraj Kabat; Dae-Ki Kim; Louis Lieto; Kerima Maasho; José Peña; Rafael Solana; John E Coligan
Journal:  Mol Immunol       Date:  2002-02       Impact factor: 4.407

7.  Human CD300C delivers an Fc receptor-γ-dependent activating signal in mast cells and monocytes and differs from CD300A in ligand recognition.

Authors:  Mariko Takahashi; Kumi Izawa; Jun-ichi Kashiwakura; Yoshinori Yamanishi; Yutaka Enomoto; Ayako Kaitani; Akie Maehara; Masamichi Isobe; Shinichi Ito; Toshihiro Matsukawa; Fumio Nakahara; Toshihiko Oki; Masunori Kajikawa; Chisei Ra; Yoshimichi Okayama; Toshio Kitamura; Jiro Kitaura
Journal:  J Biol Chem       Date:  2013-01-31       Impact factor: 5.157

8.  CD300a/c regulate type I interferon and TNF-alpha secretion by human plasmacytoid dendritic cells stimulated with TLR7 and TLR9 ligands.

Authors:  Xinsheng Ju; Martin Zenke; Derek N J Hart; Georgina J Clark
Journal:  Blood       Date:  2008-06-05       Impact factor: 22.113

9.  Functional analysis of the CD300e receptor in human monocytes and myeloid dendritic cells.

Authors:  Tamara Brckalo; Federica Calzetti; Begoña Pérez-Cabezas; Francesc E Borràs; Marco A Cassatella; Miguel López-Botet
Journal:  Eur J Immunol       Date:  2010-03       Impact factor: 5.532

10.  Functional requirements for inhibitory signal transmission by the immunomodulatory receptor CD300a.

Authors:  Karen E DeBell; Venkateswara R Simhadri; John L Mariano; Francisco Borrego
Journal:  BMC Immunol       Date:  2012-04-26       Impact factor: 3.615

View more
  9 in total

1.  Antigen presenting cell response to polysaccharide A is characterized by the generation of anti-inflammatory macrophages.

Authors:  Julie Y Zhou; David Zhou; Kevin Telfer; Kalob Reynero; Mark B Jones; John Hambor; Brian A Cobb
Journal:  Glycobiology       Date:  2022-03-19       Impact factor: 4.313

2.  Genetic Correlation Analysis and Transcriptome-wide Association Study Suggest the Overlapped Genetic Mechanism between Gout and Attention-deficit Hyperactivity Disorder.

Authors:  Om Prakash Kafle; Xi Wang; Shiqiang Cheng; Miao Ding; Ping Li; Bolun Cheng; Xiao Liang; Li Liu; Yanan Du; Mei Ma; Lu Zhang; Yan Zhao; Yan Wen; Feng Zhang
Journal:  Can J Psychiatry       Date:  2020-11-06       Impact factor: 5.321

3.  Pseudorabies Virus US3 Protein Kinase Protects Infected Cells from NK Cell-Mediated Lysis via Increased Binding of the Inhibitory NK Cell Receptor CD300a.

Authors:  K Grauwet; M Vitale; S De Pelsmaeker; T Jacob; K Laval; L Moretta; M Parodi; S Parolini; C Cantoni; H W Favoreel
Journal:  J Virol       Date:  2015-11-18       Impact factor: 5.103

4.  Monocytes Phenotype and Cytokine Production in Human Immunodeficiency Virus-1 Infected Patients Receiving a Modified Vaccinia Ankara-Based HIV-1 Vaccine: Relationship to CD300 Molecules Expression.

Authors:  Joana Vitallé; Olatz Zenarruzabeitia; Iñigo Terrén; Montserrat Plana; Alberto C Guardo; Lorna Leal; José Peña; Felipe García; Francisco Borrego
Journal:  Front Immunol       Date:  2017-07-21       Impact factor: 7.561

5.  The expression and function of human CD300 receptors on blood circulating mononuclear cells are distinct in neonates and adults.

Authors:  Olatz Zenarruzabeitia; Joana Vitallé; Susana García-Obregón; Itziar Astigarraga; Cristina Eguizabal; Silvia Santos; Venkateswara R Simhadri; Francisco Borrego
Journal:  Sci Rep       Date:  2016-09-06       Impact factor: 4.379

6.  A CD300c-Fc Fusion Protein Inhibits T Cell Immunity.

Authors:  Cheng Cui; Min Su; Yujun Lin; Laijun Lai
Journal:  Front Immunol       Date:  2018-11-15       Impact factor: 7.561

7.  T Cell Activation, Highly Armed Cytotoxic Cells and a Shift in Monocytes CD300 Receptors Expression Is Characteristic of Patients With Severe COVID-19.

Authors:  Olatz Zenarruzabeitia; Gabirel Astarloa-Pando; Iñigo Terrén; Ane Orrantia; Raquel Pérez-Garay; Iratxe Seijas-Betolaza; Javier Nieto-Arana; Natale Imaz-Ayo; Silvia Pérez-Fernández; Eunate Arana-Arri; Francisco Borrego
Journal:  Front Immunol       Date:  2021-03-11       Impact factor: 7.561

8.  CD300c is uniquely expressed on CD56 bright Natural Killer Cells and differs from CD300a upon ligand recognition.

Authors:  Milena Dimitrova; Olatz Zenarruzabeitia; Francisco Borrego; Venkateswara R Simhadri
Journal:  Sci Rep       Date:  2016-04-04       Impact factor: 4.379

9.  Multi-omics systems toxicology study of mouse lung assessing the effects of aerosols from two heat-not-burn tobacco products and cigarette smoke.

Authors:  Bjoern Titz; Justyna Szostak; Alain Sewer; Blaine Phillips; Catherine Nury; Thomas Schneider; Sophie Dijon; Oksana Lavrynenko; Ashraf Elamin; Emmanuel Guedj; Ee Tsin Wong; Stefan Lebrun; Grégory Vuillaume; Athanasios Kondylis; Sylvain Gubian; Stephane Cano; Patrice Leroy; Brian Keppler; Nikolai V Ivanov; Patrick Vanscheeuwijck; Florian Martin; Manuel C Peitsch; Julia Hoeng
Journal:  Comput Struct Biotechnol J       Date:  2020-04-25       Impact factor: 7.271

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.